Amini: They play a significant role in how we treat metastatic lung cancer. All patients with stage IV disease should have ...
Amini: From a radiation standpoint, this has changed the landscape of our field. A large proportion of my practice is stage IV disease, where patients who are on these excellent systemic therapies are ...
We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results